Improving outcomes in advanced lung cancer: Maintenance therapy in non-small-cell lung carcinoma

Muhammad Furrukh*, Ikram A. Burney, Shiyam Kumar, Khwaja F. Zahid, Mansour Al-Moundhri

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Systemic chemotherapy has remained the traditional treatment for metastatic non-small-cell lung carcinoma (NSCLC), enhancing survival rate at 1 year to 29%. The median survival had plateaued at around 10 months until early 2008, and in an attempt to enhance survival in advanced disease, maintenance chemotherapy trials were initiated which had recently demonstrated prolongation of survival by an additional 2-3 months in patients who had performance status (PS) 0-1 and well-preserved organ functions. Suitable patients with any degree of clinical benefit are treated with 4-6 cycles, and then one of the active agents is continued until best response, or toxicity (continued maintenance), or changed to a cross non-resistant single agent (switch maintenance). The article briefly reviews the evolution of systemic therapy and describes key randomised trials of maintenance therapy instituting chemotherapy and targeted agents in an attempt to improve outcomes in advanced metastatic NSCLC, based on certain clinical features, histology, and genetics.

Original languageEnglish
Pages (from-to)3-18
Number of pages16
JournalSultan Qaboos University Medical Journal
Issue number1
Publication statusPublished - Feb 2013


  • Carcinoma
  • Epidermal growth factor
  • Lung neoplasm
  • Maintenance chemotherapy
  • Molecular targeted therapy
  • Non-small-cell lung
  • Receptor
  • Vascular endothelial growth factor A

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Improving outcomes in advanced lung cancer: Maintenance therapy in non-small-cell lung carcinoma'. Together they form a unique fingerprint.

Cite this